サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1676136

慢性閉塞性肺疾患（COPD）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 184 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
慢性閉塞性肺疾患（COPD）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性閉塞性肺疾患（COPD）治療の世界市場規模は、2024年の279億1,000万米ドルから2033年には433億7,000万米ドルに成長し、2026年から2033年の予測期間中に5.02％の堅調な年間平均成長率（CAGR）を示すと予測されます。

慢性閉塞性肺疾患（COPD）治療市場は、COPDの有病率が世界的に上昇し続けていることから、大きな成長が見込まれています。COPDは、気流制限を特徴とする進行性の肺疾患であり、呼吸困難や生活の質の低下につながります。喫煙、大気汚染、職業暴露などの危険因子の増加により、気管支拡張薬、コルチコステロイド、併用療法などの効果的なCOPD治療に対する需要が高まっています。ヘルスケアプロバイダーが患者の転帰を改善し、症状を管理しようとしているため、COPD治療市場は繁栄すると予想されます。

技術の進歩はCOPD治療市場の将来を形作る上で重要な役割を果たしています。吸入器やネブライザーなどのドラッグデリバリーシステムの革新は、COPD治療薬の有効性と利便性を高めています。さらに、モバイルアプリケーションや遠隔監視装置などのデジタルヘルス技術の統合により、患者は自分の状態をより効果的に管理できるようになっています。メーカー各社が研究開発に投資を続けていることから、COPD治療市場はさまざまなヘルスケア環境において革新的なソリューションの採用が増加するとみられます。

さらに、患者の教育と自己管理を重視する傾向が強まっていることも、COPD治療市場の成長軌道に影響を与えています。患者が自分の病状や治療法について知識を深めるにつれ、効果的な自己管理を促進するリソースやサポートシステムへの需要が高まっています。この動向は、ヘルスケアプロバイダー、製薬企業、患者支援団体が協力して、患者が自分の健康を管理できるようにする教育的イニシアチブを開発する原動力となっています。市場が進化し続ける中、テクノロジー、患者エンゲージメント、個別化ケアの統合が成功の鍵となるでしょう。

当社のレポートは、様々な業界や市場に関する包括的かつ実用的な洞察をクライアントに提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 慢性閉塞性肺疾患（COPD）治療産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：薬剤クラス別

  • 概要：薬剤クラス別
  • 実績および予測データ分析：薬剤クラス別
  • 併用療法
  • 気管支拡張薬
  • コルチコステロイド
  • ホスホジエステラーゼ4型阻害薬
  • ムコキネティクス
  • その他

第6章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：タイプ別

  • 概要：タイプ別
  • 実績および予測データ分析：タイプ別
  • 慢性気管支炎
  • 肺気腫

第7章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績および予測データ分析：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 慢性閉塞性肺疾患（COPD）治療の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第9章 慢性閉塞性肺疾患（COPD）治療企業の競合情勢

  • 慢性閉塞性肺疾患（COPD）治療市場の競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.P A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKiine Plc
  • Kyowa Hakko Kirin
  • Mylan NV.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion Pharmaceuticals Inc.（Sumitomo Dainippon Pharma Co. Ltd）
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Combination Therapy Market Sales By Geography (USD MN)
  • Bronchodilators Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales By Geography (USD MN)
  • Mucokinetics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Type (USD MN)
  • Chronic Bronchitis Market Sales By Geography (USD MN)
  • Emphysema Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Obstructive Pulmonary Disease (COPD) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Combination Therapy Market Sales By Geography (USD MN)
  • Bronchodilators Market Sales By Geography (USD MN)
  • Corticosteroids Market Sales By Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales By Geography (USD MN)
  • Mucokinetics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Type (USD MN)
  • Chronic Bronchitis Market Sales By Geography (USD MN)
  • Emphysema Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11218849

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is anticipated to grow from USD 27.91 Billion in 2024 to USD 43.37 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.02% during the forecast period of 2026 to 2033.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.

Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • COMPANIES PROFILED
  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKiine plc
  • Kyowa Hakko Kirin
  • Mylan NV.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data Analysis By Drug Class
  • 5.3. Combination Therapy Historic and Forecast Sales By Regions
  • 5.4. Bronchodilators Historic and Forecast Sales By Regions
  • 5.5. Corticosteroids Historic and Forecast Sales By Regions
  • 5.6. Phosphodiesterase Type 4 Inhibitor Historic and Forecast Sales By Regions
  • 5.7. Mucokinetics Historic and Forecast Sales By Regions
  • 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY TYPE

  • 6.1. Overview By Type
  • 6.2. Historical and Forecast Data Analysis By Type
  • 6.3. Chronic Bronchitis Historic and Forecast Sales By Regions
  • 6.4. Emphysema Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data Analysis By Distribution Channel
  • 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT COMPANIES

  • 9.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Almirall
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. AstraZeneca
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Boehringer Ingelheim International GmbH
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. CHIESI Farmaceutici S.P A.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. F. Hoffmann-La Roche Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. GlaxoSmithKiine Plc
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Kyowa Hakko Kirin
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Mylan NV.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Novartis AG
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Orion Corporation
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Sanofi
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Teva Pharmaceutical Industries Ltd.
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. Theravance Biopharma
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Verona Pharmaceuticals
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies